Cara Therapeutics (CARA) Bullish Stance Reiterated at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Cara Therapeutics, Inc. (CARA) Posts Mixed Q4 Results
March 27, 2014 4:03 PM EDTCara Therapeutics, Inc. (NASDAQ: CARA) reported Q4 EPS of ($0.49), $0.31 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.52 million.
For earnings history and earnings-related data on (not found) (CARA) click here.... More
